These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33197187)

  • 1. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
    Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
    J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
    Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
    Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
    Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel glucopyranoside C2-derived 1,2,3-triazoles displaying selective inhibition of O-GlcNAcase (OGA).
    Igual MO; Nunes PSG; da Costa RM; Mantoani SP; Tostes RC; Carvalho I
    Carbohydr Res; 2019 Jan; 471():43-55. PubMed ID: 30412832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate.
    Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA
    J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
    Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
    [No Abstract]   [Full Text] [Related]  

  • 8. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.
    Li T; Li Z; Li J; Wang J; Guo L; Wang PG; Zhao W
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6854-7. PubMed ID: 23058883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice.
    Pan D; Gu JH; Zhang J; Hu Y; Liu F; Iqbal K; Cekic N; Vocadlo DJ; Dai CL; Gong CX
    J Alzheimers Dis; 2021; 81(1):273-286. PubMed ID: 33814439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
    Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
    Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 4-(Arylethynyl)piperidine Derivatives as Potent Nonsaccharide
    Cheng Z; Shang N; Wang X; Kang Y; Zhou J; Lan J; Hu J; Peng Y; Xu B
    J Med Chem; 2024 Aug; 67(16):14292-14312. PubMed ID: 39109492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors.
    Bergeron-Brlek M; Goodwin-Tindall J; Cekic N; Roth C; Zandberg WF; Shan X; Varghese V; Chan S; Davies GJ; Vocadlo DJ; Britton R
    Angew Chem Int Ed Engl; 2015 Dec; 54(51):15429-33. PubMed ID: 26545827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Novel and Brain-Penetrant
    Tawada M; Fushimi M; Masuda K; Sun H; Uchiyama N; Kosugi Y; Lane W; Tjhen R; Endo S; Koike T
    J Med Chem; 2021 Jan; 64(2):1103-1115. PubMed ID: 33404239
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation.
    Martin JC; Fadda E; Ito K; Woods RJ
    Glycobiology; 2014 Jan; 24(1):85-96. PubMed ID: 24134879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds.
    Dorfmueller HC; van Aalten DM
    FEBS Lett; 2010 Feb; 584(4):694-700. PubMed ID: 20026047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
    Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
    Li B; Li H; Hu CW; Jiang J
    Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-GlcNAcase: promiscuous hexosaminidase or key regulator of O-GlcNAc signaling?
    Alonso J; Schimpl M; van Aalten DM
    J Biol Chem; 2014 Dec; 289(50):34433-9. PubMed ID: 25336650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a compensatory regulation of colonic O-GlcNAc transferase and O-GlcNAcase expression in response to disruption of O-GlcNAc homeostasis.
    Decourcelle A; Loison I; Baldini S; Leprince D; Dehennaut V
    Biochem Biophys Res Commun; 2020 Jan; 521(1):125-130. PubMed ID: 31630803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis.
    Wang X; Feng Z; Wang X; Yang L; Han S; Cao K; Xu J; Zhao L; Zhang Y; Liu J
    Diabetologia; 2016 Jun; 59(6):1287-96. PubMed ID: 26993634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.